Novartis to buy Imperial-Crick spinout Myricx Bio for up to $1.5 billion

The London biotech went from a 2019 GBP 4.5 million seed round to a pharma exit after shifting NMT inhibitors into ADC payloads.

By · Published

Illustration of Novartis integrating Myricx Bio's molecular technology, showing Myricx biotech elements merging into the Novartis emblem.

The London biotech went from a 2019 GBP 4.5 million seed round to a pharma exit after shifting NMT inhibitors into ADC payloads.